Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

1 Jun 2017

Abstract excerpt

Hemophilia A (HA) is a common bleeding disorder caused by the deficiency of factor VIII (FVIII) with an incidence of ~1 in 5000 male births. Replacement of FVIII is necessary to prevent and treat bleeding episodes. However, with multiple new drugs in addition to old standards, choosing among the different FVIII treatment options is harder than ever. There are FVIII products that are plasma derived or recombinant,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemophilia Treatment and Research
Share to Platelet Disorders and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28670147
DOI: 10.2147/jbm.s103796

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?PMID 28670147Read ↗

The long and short of it: using the new factor products.Semantic proximity Read ↗

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and ChallengesSemantic proximity Read ↗

Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing TherapiesSemantic proximity Read ↗

Emerging therapies for hemophilia: controversies and unanswered questionsSemantic proximity Read ↗

Acquired hemophilia A: Updated review of evidence and treatment guidance.Semantic proximity Read ↗

Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Semantic proximity Read ↗

Emerging and future therapies for hemophiliaSemantic proximity Read ↗

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity Read ↗

Extending half-life in coagulation factors: where do we stand?Semantic proximity Read ↗

Diagnosis and management of hemophilia A and B.Semantic proximity Read ↗

Key insights to understand the immunogenicity of FVIII products.Semantic proximity Read ↗

Development of inhibitors in hemophilia A: An illustrated reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.